Charles Tee Fact checked by:Thailand Medical News Team Sep 04, 2024 3 months, 1 week, 22 hours, 15 minutes ago
Vaccine News: In the quest to enhance the effectiveness of vaccines, researchers from The Ohio State University-USA and Helwan University-Egypt have made a significant breakthrough with a novel adjuvant called Bordetella colonization factor A (BcfA). This adjuvant, derived from the Gram-negative bacterium Bordetella bronchiseptica, has shown promise in activating immune responses that could lead to better protection against various infectious diseases. This
Vaccine News report explores the key findings of their study and the potential impact of BcfA on vaccine development.
BcfA - A new hope for vaccines in fighting infectious diseases
The Role of Adjuvants in Vaccines
Vaccines are one of the most effective tools in combating infectious diseases. However, the efficacy of vaccines often depends on the inclusion of adjuvants - substances that enhance the body’s immune response to an antigen. Traditional adjuvants, like alum (aluminum-based compounds), have been used for decades to boost immune responses, but they are not without limitations. Alum, for instance, tends to promote a type of immune response known as TH2, which is not always the most effective against certain pathogens.
BcfA stands out because it does not elicit a TH2 response. Instead, it promotes TH1 and TH17 immune responses, which are more effective in protecting against both bacterial and viral infections. The study's researchers, including those from The Ohio State University’s Departments of Microbial Infection and Immunity and Helwan University’s Faculty of Pharmacy, sought to understand how BcfA works and how it could be used to improve vaccines.
Mechanisms of BcfA Activation
The study found that BcfA activates antigen-presenting cells (APCs), a critical component of the immune system. APCs, such as dendritic cells, process antigens and present them to T cells, initiating an immune response. BcfA was shown to activate APCs through the Toll-like receptor 4 (TLR4), a protein known to play a key role in the body's defense against pathogens.
When BcfA was introduced to bone marrow-derived dendritic cells (BMDCs) from mice, the cells exhibited increased expression of costimulatory molecules like CD40, CD80, and CD86. These molecules are essential for T cell activation and subsequent immune responses. Furthermore, BcfA-treated BMDCs produced cytokines such as IL-6, TNF-α, and IL-12/23 p40, which are crucial for driving TH1 and TH17 responses.
Human Cell Response to BcfA
The study didn’t stop with mice; it also tested BcfA's effects on human cells. Peripheral blood mononuclear cells (PBMCs) from adult donors were exposed to BcfA, and the results were promising. The cells produced IL-6, a cytokine involved in promoting TH1 and TH17 responses. This finding suggests that BcfA could potentially be effective in human vaccines, offering a new tool for enhancing immune responses without triggering TH2-associated side effects.
t;Enhancing Antigen Presentation
One of the critical aspects of an effective vaccine is its ability to ensure that antigens are properly presented to the immune system. The study demonstrated that BcfA improves the uptake and processing of antigens by APCs. In experiments with BMDCs, cells treated with BcfA showed increased uptake of a model antigen, DQ-OVA, indicating that BcfA could help present antigens more effectively to T cells.
Implications for Vaccine Development
The potential applications of BcfA in vaccine development are vast. Traditional vaccines often rely on adjuvants that promote a mixed TH1/TH2 response. However, for certain pathogens, a more targeted immune response, such as TH1 or TH17, may be necessary for long-lasting protection. The study highlights that BcfA's ability to suppress TH2 responses while enhancing TH1 and TH17 responses makes it an attractive candidate for vaccines against diseases where these immune pathways are crucial.
Moreover, BcfA’s ability to function without eliciting a strong TH2 response could also reduce the risk of vaccine-associated adverse events. Conditions like antibody-dependent enhancement of disease (ADE) and vaccine-associated enhancement of respiratory disease (VAERD) are linked to TH2 responses, and BcfA’s properties might mitigate these risks.
Future Directions and Conclusion
The study’s findings open up exciting possibilities for future vaccine research. The researchers plan to continue exploring BcfA’s potential, particularly its ability to directly activate T cells when included in vaccine formulations. This could further amplify the immune response, making vaccines even more effective.
In conclusion, the study findings provides valuable insights into how BcfA functions as an adjuvant and its potential to revolutionize vaccine development. By promoting TH1 and TH17 responses while attenuating TH2 responses, BcfA offers a promising avenue for creating safer and more effective vaccines.
The study findings were published in the peer-reviewed journal: Frontiers in Immunology.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1439418/full
For the latest Vaccine News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/china-to-launch-circular-rna-vaccines-soon
https://www.thailandmedical.news/news/peer-reviewed-study-warns-that-covid-19-vaccines-are-causing-endotheliopathy-or-glycocalyx-degradation
Share
Tweet
Share
